leisure time -WSS

leisure time

author：Wikipedia 2025-09-29 12:09:38 - browse：8

Without question, the new federal law banning surprise billing is achieving its goal of protecting patients from enormous medical bills. But in doing so, the measure, which was initially projected to lower federal spending, appears to be raising costs elsewhere.

The Biden administration’s new progress report on the process for arbitrating disagreements between insurance companies and providers, which covers the first six months of 2023, shows that in over 80% of payment disputes, the arbiter settled on an amount that was more than the median in-network rate for that service. In other words, insurers were ordered to pay more to an out-of-network provider than they’d pay to a contracted one. Not only that, the sheer volume of disputes means the three federal agencies that run the program are devoting much more time to it than expected.

“It raises concerns for folks that envisioned the arbitration process as helping to moderate costs rather than be a tool these companies can leverage to obtain even higher payments,” said Zachary Baron, the director of Georgetown University’s Health Policy and Law Initiative.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Anesthesiologist group: stop taking Ozempic before surgery
Next article： Francis Collins on trust in science and how Covid communications failed

WSS

Vertex non

How digital therapeutics firms are pivoting after Pear's bankruptcy

General Catalyst, Summa Health deal will turn on physician buy

NIH director takes cautious approach to Biden drug pricing priority

Why doctors need education on FDA device approval process

eGenesis tests gene

explore

leisure time

explore

Malaria cases in Florida and Texas: Here’s what you need to know

Medicare Advantage today, explained in one chart

What does generative AI mean for health care? We asked experts

Medicare Advantage today, explained in one chart

Virginia high school admissions case could be legal follow

Novo Nordisk to expand supply of Wegovy for U.S. patients

Cancer drug shortages should be causing more outrage

Research misconduct: Proposed new rules face resistance

At least 13 dead in Texas as scorching temps continue

Elizabeth Holmes banned from government health programs

knowledge

Do digital therapeutics have a future in medicine?

Cognito secures funding to test medical device for Alzheimer's

The lessons of Aduhelm, an Alzheimer's drug that was not to be

Covid misinformation case heads to Supreme Court

What to make of Gilead’s Trodelvy troubles and Elevation Oncology’s rise

What to make of Gilead’s Trodelvy troubles and Elevation Oncology’s rise

focus

entertainment

entertainment

hotspot